Epinephrine intranasal spray - Bryn Pharma
Alternative Names: BRYN-NDS1C; UTULY™Latest Information Update: 28 Jan 2025
Price :
$50 *
At a glance
- Originator Bryn Pharma
- Class Anti-infectives; Antiallergics; Antiasthmatics; Bronchodilators; Catecholamines; Ethanolamines; Skin disorder therapies; Small molecules
- Mechanism of Action Alpha adrenergic receptor agonists; Beta adrenergic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaphylaxis
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for clinical-Phase-Unknown development in Anaphylaxis(In volunteers) in USA (Intranasal, Spray)
- 01 Apr 2024 Updated pharmacodynamics data from a phase III trial in Anaphylaxis presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)
- 23 Feb 2024 Pharmacokinetics data from a phase I trial in Anaphylaxis presented at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)